Results
Among 249 requests for CCP during the study period, 225 (78%) were
accepted and 81 (36%) had available follow-up until d28 at time of
study analysis. Six patients were excluded because they finally did not
receive any CCP despite a positive answer to CCP request (2 sotrovimab
treatment, 1 intensive care physician’s refusal, 2 spontaneous
improvements, and 1 premature death). A total of 75 (33%) patients were
analyzed (Table 1) . The most frequent underlying
immunodeficiency was HM (69%) and most patients had received B-cell
depletion therapy such as rituximab (68%). The remaining patients were
SOTR (16%) or had AID (12%). Of note, 91% of the cohort was
vaccinated with at least two doses. An anti SARS-CoV2 Spike protein
antibodies > 260 BAU/mL was reported in 11% of patients,
with a higher rate in SOTR (33%, vs 6% in HM and 11% in AID;
p=0.03).
C-reactive protein decreased significantly between d0 and d7 after CCP
infusion (101 (CI 79-124) vs 37 (CI 25-48) mg/L, p<
0.0001). At d7, 48 patients (64%) improved their conditions, 16 (21%)
were discharged from hospital, 7 (10%) have been transferred to
intensive care unit, and 6 (8%) had died. At day 28, the OS of whole
cohort was 76% (CI = 65-84). The type of underlying immunosuppression
did not impact OS (77% (95 % CI = 63-86) for HM, 82% (95 % CI =
45-95) for AID, and 71% (95 % CI = 88-40) for SOTR, p=0.84), whereas
OS was higher in patient with WHO score 5 compared to WHO score 6 at the
day of CCP infusion (88 % (95 % CI = 94-75) vs 53 % (95 % CI =
69-29), p =0.0009) (Figure 1) .